PhD Project: Optimising Treatment Outcomes in Multiple Sclerosis with Ocrelizumab

Background:

Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder that leads to significant disability. The introduction of high-efficacy disease-modifying therapies (DMTs) has transformed MS management, yet treatment selection remains complex. Ocrelizumab, a B-cell-depleting therapy, is widely used, but its effectiveness compared to other DMTs and the variability in B-cell repopulation dynamics are not fully understood. Understanding these factors is critical for optimising individualised treatment strategies.

Aims:

1. To compare disability and relapse outcomes in patients with relapsing MS treated with ocrelizumab versus high-efficacy and moderate-efficacy DMTs, including in specific clinical scenarios.

2. To evaluate the variability and clinical predictors of B-cell repopulation in patients treated with ocrelizumab and assess whether B-cell repopulation is associated with MS disease activity.

Impact:

This research will provide crucial insights into the comparative effectiveness of ocrelizumab and its immunological effects, enabling more personalised treatment strategies. The findings will help refine clinical decision-making, improve patient outcomes, and contribute to the evolving landscape of MS therapeutics.

This PhD project is suitable for students with interest in statistics and research of treatment effectiveness. During the projects, you will learn some of the more advanced statistical techniques. Knowledge of elementary statistics is a requisite. The offer of the project is conditional on a successful application for a University of Melbourne scholarship.

Dr

Izanne Roos

Senior Research Fellow in Multiple Sclerosis

Department of Medicine

Dr

Izanne Roos

Contact Izanne

Division

Faculty of Medicine, Dentistry and Health Sciences

Dr

Izanne Roos

Print

Izanne's Short Profile

Enquiries

Contact